Compounding pharmacies assign BUDs based on United States Pharmacopeia (USP) guidelines, specifically USP Chapter 797 for sterile preparations
For people with pre-existing liver concerns, GLP-1 agonists can be part of therapeutic intervention
Research shows modest, incremental HbA1c reductions (typically 0.30.8%) when adding a DPP-4 inhibitor to a GLP-1 drug, but many patients achieve superior glucose control by simply increasing their GLP-1 dose or switching to a dual-agonist like tirzepatide
Ice crystal formation physically damages the peptide structure, creating aggregation and reducing biological activity
In fact, a recent examination of patient perspectives of injectable treatments currently available for the treatment of T2D identified several characteristics of these treatments that are most important to patients, namely confidence in delivering the correct dose, ease of administering the correct dose, ease of using the injection device, and dose frequency [52]